Search Result

Results for "

Bd

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Akt (1) AMPK (1) Amyloid-β (1) Antibiotic (1) Apoptosis (15) Bacterial (11) Bcl-2 Family (1) Biochemical Assay Reagents (6) c-Fms (1) c-Myc (5) Caspase (2) CDK (3) Cytochrome P450 (1) Discoidin Domain Receptor (1) DNA/RNA Synthesis (1) Dopamine Receptor (2) Drug Metabolite (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (2) Epigenetic Reader Domain (161) Fluorescent Dye (4) Fungal (2) GLUT (1) Histone Acetyltransferase (3) HIV (4) HSP (1) Interleukin Related (5) Isotope-Labeled Compounds (10) JAK (1) JNK (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (5) mAChR (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Molecular Glues (4) NF-κB (2) Nucleoside Antimetabolite/Analog (2) p38 MAPK (2) PAK (1) Phosphatase (1) PI3K (4) Polo-like Kinase (PLK) (1) PPAR (1) PROTAC Linkers (1) PROTACs (32) Pyroptosis (1) Reactive Oxygen Species (ROS) (1) Reference Standards (4) SARS-CoV (1) Sigma Receptor (10) STAT (2) SWI/SNF Complex (3) Target Protein Ligand-Linker Conjugates (1) TNF Receptor (3) Topoisomerase (2) Trk Receptor (1) TRP Channel (3) VEGFR (1)
By Research Areas:	Cancer (143) Cardiovascular Disease (4) Endocrinology (6) Infection (16) Inflammation/Immunology (42) Metabolic Disease (5) Neurological Disease (20)
Click Chemistry:	PROTAC Synthesis (1)
Oligonucleotides:	Nucleoside Analogs (2)

224

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107425

MZ 1 20+ Cited Publications	PROTACs Epigenetic Reader Domain	Cancer
MZ 1 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. K_ds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively .

HY-16954

ARV-825 Maximum Cited Publications 35 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
ARV-825 is a PROTAC connected by ligands for Cereblon and BRD4. ARV-825 binds to BD1 and BD2 of BRD4 with K_ds of 90 and 28 nM, respectively.

HY-16652

Apabetalone 5+ Cited Publications RVX-208; RVX000222	Epigenetic Reader Domain HIV	Cancer
Apabetalone (RVX-208) is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. The IC₅₀s are 87 μM and 0.51 μM for *BD1* and *BD2*, respectively .

HY-136570

GSK778 1 Publications Verification iBET-Bd1	Epigenetic Reader Domain Apoptosis	Inflammation/Immunology Cancer
GSK778 (iBET-BD1), a chemical probe, is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC₅₀s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively. GSK778 phenocopies the effects of pan-BET inhibitors in cancer models .

HY-111139

MS417 4 Publications Verification GTPL7512	Epigenetic Reader Domain HIV	Infection Inflammation/Immunology
MS417 is a selective BET-specific BRD4 inhibitor, binds to BRD4-BD1 and BRD4-BD2 with IC₅₀s of 30, 46 nM and K_ds of 36.1, 25.4 nM, respectively, with weak selectivity at CBP BRD (IC₅₀, 32.7 μM).

HY-16996A

BD-1047 dihydrobromide 10+ Cited Publications	Sigma Receptor	Neurological Disease
BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors. BD-1047 dihydrobromide attenuates Apomorphine (HY-12723)-induced climbing and Phencyclidine-induced head twitches .

HY-18101A

BD-1063 dihydrochloride 3 Publications Verification	Sigma Receptor TRP Channel	Neurological Disease
BD-1063 dihydrochloride is a selective σ-1 receptor antagonist with inhibitory activity against TRPC5 and TRPM3. BD-1063 dihydrochloride exerts anti-hyperalgesic and anti-allodynic effects by inhibiting sustained calcium influx mediated by TRPC5 and TRPM3, and reverses the effects of Carrageenan (HY-125474). BD-1063 dihydrochloride also significantly reduces excessive ethanol self-administration behavior. BD-1063 dihydrochloride is widely used in studies on the mechanisms underlying neuropathic pain, inflammatory hyperalgesia, and alcohol abuse and dependence .

HY-151594

iBRD4-BD1	Epigenetic Reader Domain	Inflammation/Immunology Cancer
iBRD4-BD1 is selective BRD4 bromodomain inhibitor. iBRD4-BD1 has inhibition activity for BRD4 bromodomain with an IC₅₀ value of 12 nM. iBRD4-BD1 can be used for the research of inflammation and oncology .

HY-136571

GSK046 3 Publications Verification iBET-Bd2	Epigenetic Reader Domain	Inflammation/Immunology
GSK046 (iBET-BD2), a chemical probe, is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins, with IC₅₀s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively. GSK046 has immunomodulatory activity .

HY-131140

BD750 5 Publications Verification	JAK STAT	Inflammation/Immunology Cancer
BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC₅₀ values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively .

HY-107424

BAY-299 4 Publications Verification	Epigenetic Reader Domain	Cancer
BAY-299, a chemical probe, is a very potent, dual inhibitor with IC₅₀s of 67 nM for BRPF2 bromodomains (BD), 8 nM for TAF1 BD2, and 106 nM for TAF1L BD2.

HY-145550

Amredobresib BI894999	Epigenetic Reader Domain	Cancer
Amredobresib (BI894999) is an orally active BET inhibitor. Amredobresib inhibits the binding of *BRD4-BD1* and *BRD4-BD2* bromodomains to acetylated histones with IC₅₀ values of 5 nM and 41 nM, respectively. Amredobresib exhibits anticancer activity against acute myeloid leukemia (AML) and NUT cancer .

HY-136857

BRD4 degrader-3	Epigenetic Reader Domain	Cancer
BRD4 degrader-3 is a potent bromodomain BRD4 degrader extracted from patent WO2020055976A1, example 1a, has IC₅₀s of 15.5 and 12.3 nM for BRD4-BD1 and BRD4-BD2, respectively . PROTAC BRD4 Degrader-7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135608

BD-1008	Sigma Receptor	Neurological Disease
BD-1008 is a nonselective σ receptor antagonist with K_is against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 has an extremely low affinity for the D2 receptor (K_i = 1112 nM) and dopamine transporter (DAT) (K_i > 10,000 nM). BD-1008 significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 blocks the self-administration behavior of σ agonists.BD-1008 can be used for the study of addiction therapy that target the σ receptor .

HY-149878

BD-9136	PROTACs Epigenetic Reader Domain	Cancer
BD-9136 is a potent and highly selective BRD4 PROTAC depressant. BD-9136 has low-nanomolar degradation potencies against BRD4 , and its degradation selectivity for BRD4 is 1000 times that of BRD2 and BRD3 proteins. BD-9136 has antitumor activity .(Pink: Desmethyl-QCA276 (HY-44103); Black: 3-(2-(4-Methylpiperazin-1-yl)ethyl)azetidin-3-ol; Blue: Thalidomide-4-OH (HY-103596))

HY-120000

MS402 2 Publications Verification	Epigenetic Reader Domain	Inflammation/Immunology Cancer
MS402 is a *BD1*-selective BET BrD inhibitor with K_is of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for *BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1)* and *BRD2(BD2)*, respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice .

HY-112429

HJB97 2 Publications Verification	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
HJB97 is a high-affinity BET inhibitor with K_i values of 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), and 1.0 nM (BRD4 BD2) . HJB97 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC BET degraders with antitumor activity . HJB97 can be used for the synthesis of BETd-260 (HY-101519).

HY-151593

dBRD4-BD1	PROTACs Epigenetic Reader Domain	Cancer
dBRD4-BD1 is a selective and durable BRD4 degrader with an DC₅₀ value of 280 nM (D_max=77%). dBRD4-BD1 upregulates BRD2/3 protein level and shows low cytotoxicity than iBRD4-BD1 .

HY-151538

PBRM1-BD2-IN-8	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-8 (compound 34) is a potent PBRM1 Bromodomain inhibitor (PBRM1-BD2 K_d=4.4 μM, PBRM1-BD2 IC₅₀=0.16 μM; PBRM1-BD5 K_d=25 μM). PBRM1-BD2-IN-8 shows anti-cancer activity .

HY-44012A

SMARCA-BD ligand 1 for PROTAC dihydrochloride 1 Publications Verification	Ligands for Target Protein for PROTAC SWI/SNF Complex	Cancer
SMARCA-BD ligand 1 for PROTAC dihydrochloride is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC .

HY-44012

SMARCA-BD ligand 1 for PROTAC 1 Publications Verification	Ligands for Target Protein for PROTAC SWI/SNF Complex	Cancer
SMARCA-BD ligand 1 for PROTAC is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC .

HY-19760

I-BET282	Epigenetic Reader Domain	Inflammation/Immunology
I-BET282 is a pan-inhibitor of all eight BET bromodomains, and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC₅₀s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD) .

HY-125232

MS645 1 Publications Verification	Epigenetic Reader Domain	Cancer
MS645 is a bivalent BET bromodomains (BrD) inhibitor with a K_i of 18.4 nM for BRD4-BD1/BD2. MS645 spatially constrains bivalent inhibition of BRD4 BrDs resulting in a sustained repression of BRD4 transcriptional activity in solid-tumor cells .

HY-151532

PBRM1-BD2-IN-5	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-5 is a potent PBRM1 Bromodomain inhibitor with K_d values of 1.5 μM and 3.9 μM for PBRM1-BD2 and PBRM1-BD5, respectively, and an IC₅₀ value of 0.26 μM for PBRM1-BD2. PBRM1-BD2-IN-5 reduces the binding of full-length PBRM1 within the PBAF complex in cell lysates to acetylated histone peptide. PBRM1-BD2-IN-5 can be used to research anticancer .

HY-171179

BD-Oligo	Fluorescent Dye	Neurological Disease
BD-Oligo is an oligomer-specific fluorescent chemical probe. BD-Oligo preferentially identifies Aβ oligomer assemblies over monomers or fibrils by using diversity-directed fluorescent library (DOFL) screening and computational techniques. BD-Oligo exhibits dynamic oligomer monitoring capabilities during Aβ peptide fibril formation as Aβ is induced to form oligomers and ultimately fibrils over time. BD-Oligo also exhibits blood-brain barrier permeability with the ability to stain Aβ oligomers in vivo .

HY-114504

RVX-297	Epigenetic Reader Domain	Inflammation/Immunology
RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for *BD2. RVX-297 shows IC₅₀s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2*), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models .

HY-138563

GSK973	Epigenetic Reader Domain	Cancer
GSK973, a chemical probe, is a highly selective, orally bioavailable inhibitor of the *BD2s* (second bromodomains) of the BET family, with a pIC₅₀ of 7.8 and a pK_d of 8.7 for BRD4 BD2. GSK973 displays a 1600-fold selectivity for BRD4 BD2 over BRD4 BD1. GSK973 shows good potency against BRD2 BD2, BRD3 BD2, and BRDT BD2 (pIC₅₀=7.4~7.8; pK_d=8.3~8.5) .

HY-112150

ZL0454 2 Publications Verification	Epigenetic Reader Domain	Inflammation/Immunology
ZL0454 is a potent and selective Bromodomain-containing protein 4 (BRD4) inhibitor with an IC₅₀ of 49 and 32 nM for BD1 and BD2.

HY-178041

BRD4-BD1/2-IN-3	Epigenetic Reader Domain Interleukin Related c-Fms NF-κB TNF Receptor	Inflammation/Immunology
BRD4-BD1/2-IN-3 (Compound B6) is a selective BRD4 BD2 inhibitor with an IC₅₀ of 0.41  nM for BRD4 BD2 over BRD4 BD1. BRD4-BD1/2-IN-3 significantly inhibits the LPS (HY-D1056)-induced expression of IL-6. BRD4-BD1/2-IN-3 shows anti-inflammatory activities by modulating the TNF and NF-κB signaling pathway. BRD4-BD1/2-IN-3 can be used for inflammatory diseases research .

HY-112149

ZL0420	Epigenetic Reader Domain	Inflammation/Immunology
ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC₅₀ values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.

HY-175678

PROTAC BRD2 BD1 Degrader-1	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD2 BD1 Degrader-1 (compound 21-1) is a potent and selective BRD2 BD1 PROTAC degrader. PROTAC BRD2 BD1 Degrader-1 induces the association of BRD2 BD1 and von Hippel–Lindau-elongin C-elongin B (VCB). (Pink: BRD2-BD1 Ligand (HY-175679); Blue: E3 ligase ligand (HY-125845); Black: Linker (HY-W069332)) .

HY-44012B

SMARCA-BD ligand 1 for PROTAC hydrochloride 1 Publications Verification	Ligands for Target Protein for PROTAC SWI/SNF Complex	Cancer
SMARCA-BD ligand 1 hydrochloride for PROTAC is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC .

HY-151531

PBRM1-BD2-IN-4	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-4 (compound 15) is a potent PBRM1 Bromodomain inhibitor with K_d values of 5.5 μM and 11.1 μM for PBRM1-BD2 and PBRM1-BD5, respectively, and an IC₅₀ value of 0.2 μM for PBRM1-BD2. PBRM1-BD2-IN-4 can be used to research anticancer .

HY-151528

PBRM1-BD2-IN-1	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-1 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-1 has binding affinity and inhibitory activity for PBRM1-BD2 with K_d and IC₅₀ values of 0.7 μM and 0.2 μM, respectively. PBRM1-BD2-IN-1 can be used for the research of cancer .

HY-151549

Mtb-cyt-bd oxidase-IN-2	Bacterial	Infection
Mtb-cyt-bd oxidase-IN-2 is an inhibitor of Mycobacterium tuberculosis cytochrome bd oxidase (Mtb cyt-bd oxidase) with an IC₅₀ value of 0.67 μM. Mtb-cyt-bd oxidase-IN-2 inhibits the growth of Mycobacterium tuberculosis with a MIC value of 256 μM. Mtb-cyt-bd oxidase-IN-2 can be used for the research of infection .

HY-159007

BD-AcAc2 R,S-1,3-Butanediol acetoacetate diester	Pyroptosis	Cardiovascular Disease Metabolic Disease
BD-AcAc2 is an orally active antiepileptic. BD-AcAc2 results in body weight loss or maintenance with moderate increases in circulating ketones .

HY-111977

ZEN-3219	Epigenetic Reader Domain	Cancer
ZEN-3219 is a BET inhibitor with IC₅₀s of 0.48, 0.16 and 0.47 μM for *BRD4(BD1), BRD4(BD2)* and *BRD4(BD1BD2), respectively. ZEN-3219 can be used to form PROTAC*s to induce degradation of BRD4 .

HY-111979

ZEN-3411	Epigenetic Reader Domain	Cancer
ZEN-3411 is a BET inhibitor with IC₅₀s of 0.05, 0.05 and 0.06 μM for *BRD4(BD1), BRD4(BD2)* and *BRD4(BD1BD2), respectively. ZEN-3411 can be used to form PROTAC*s to induce degradation of BRD4 .

HY-111978

ZEN-3862	Epigenetic Reader Domain	Cancer
ZEN-3862 is a BET inhibitor with IC₅₀s of 0.16 and 0.13 μM for BRD4(BD1) and BRD4(BD2) , respectively. ZEN-3862 can be used to form PROTACs to induce degradation of BRD4 .

HY-P991000

Imneskibart AU-007; Bd-8; BdG8	Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-148750

PTX-BD10-2 Bd10-2	Trk Receptor	Neurological Disease
PTX-BD10-2 (BD10-2) is an orally active TrkB/C modulator. PTX-BD10-2 ameliorates BFCN degeneration. PTX-BD10-2 restores cholinergic neurite integrity, alleviates cholinergic neurite atrophy. PTX-BD10-2 can be used in the research of Alzheimer's disease .

HY-100966

BD-1008 dihydrobromide	Sigma Receptor	Neurological Disease
BD-1008 dihydrobromide is a nonselective σ receptor antagonist with K_is against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 dihydrobromide has an extremely low affinity for the D2 receptor (K_i = 1112 nM) and dopamine transporter (DAT) (K_i > 10,000 nM). BD-1008 dihydrobromide significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 dihydrobromide blocks the self-administration behavior of σ agonists.BD-1008 dihydrobromide can be used for the study of addiction therapy that target the σ receptor .

HY-136570A

GSK778 hydrochloride iBET-Bd1 hydrochloride	Apoptosis Epigenetic Reader Domain	Inflammation/Immunology Cancer
GSK778 (iBET-BD1) hydrochloride is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC₅₀s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively .

HY-143300

BRD4-BD1-IN-2	Epigenetic Reader Domain	Cardiovascular Disease Cancer
BRD4-BD1-IN-2 is a selective *BRD4-BD1* inhibitor, with an IC₅₀ of 2.51 µM (20-times greater than that of *BD2). BRD4-BD1-IN-2* can be used in studies of cancer and cardiovascular diseases .

HY-151529

PBRM1-BD2-IN-2	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-2 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-2 has binding affinity and inhibitory activity for PBRM1-BD2 with K_d and IC₅₀ values of 9.3 μM and 1.0 μM, respectively. PBRM1-BD2-IN-2 can be used for the research of cancer .

HY-151956

Mtb-cyt-bd oxidase-IN-7	Bacterial	Infection
Mtb-cyt-bd oxidase-IN-7 is a cytochrome bd terminal oxidase (Cyt-bd) inhibitor with a K_d value of 4.17 μM. Mtb-cyt-bd oxidase-IN-7 shows anti-tuberculosis activities .

HY-151533

PBRM1-BD2-IN-6	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-6 is a potent PBRM1 bromodomain inhibitor with an IC₅₀ value of 0.22 μM. PBRM1-BD2-IN-6 shows antiproliferation activity. PBRM1-BD2-IN-6 has the potential for the research of PBRM1-dependent cancer .

HY-142675

BRD4-BD1/2-IN-2	Epigenetic Reader Domain	Cancer
BRD4-BD1/2-IN-2 is a potent BRD4 BD2 inhibitor with IC₅₀s of <0.5 nM and <300 nM for BRD4 BD2 and BRD4 BD1, respectively (WO2021233371A1, compound 2) .

HY-129201

ZEN-2759	Epigenetic Reader Domain	Cancer
ZEN-2759 is a potent BET (Bromodomain and Extra-Terminal Domain) inhibitor, with IC₅₀ values of 0.23, 0.08 and 0.28 μM for *BRD4(BD1), BRD4(BD2), and BRD4(BD1BD2)*, respectively .

HY-147573

BRD4 Inhibitor-23	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-23 is a potent and orally active BRD4 inhibitor with IC₅₀s of 6.21 nM and 1.44 nM for BRD4 BD-1 and BRD4 BD-2, respectively (WO2022033542A1; Example 1) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3213

Naringenin triacetate	Flavonoids Classification of Application Fields Flavonones Rutaceae Plants Disease Research Fields Citrus Cancer Source Classification	Epigenetic Reader Domain
Naringenin triacetate is a flavonoid isolated from plant, exhibits a good binding affinity with multiple crystal structures of first bromodomain BRD4 (BRD4 BD1) .

HY-107302

Sandosaponin A Soyasaponin Bd	Triterpenes Leguminosae Terpenoids Plants Phaseolus vulgaris Linn. Source Classification	Endogenous Metabolite
Sandosaponin A (Soyasaponin Bd) is a saponin with inhibitory activity against human recombinant aldehyde reductase (hAKR1B1). Sandosaponin A can inhibit the reduction of l-idose and 4-hydroxynonenal to varying degrees. The presence of Sandosaponin A reveals the challenges posed by the masking effect of conventional aldehyde reductase inhibitors in mixtures when exploring differential aldehyde reductase inhibitors. The inhibitory mechanism of Sandosaponin A may be related to its mode of action on different substrates .

HY-177139

CDD-1349	other families Phenols Polyphenols Plants Pteris multifida Poir. Source Classification	Epigenetic Reader Domain
CDD-1349 (Compound 15) is a *BRDT-BD2/BRD4-BD2* selective inhibitor. CDD-1349is an analog with sixfold selectivity for BRDT-BD2 versus BRD4-BD2. CDD-1349 has an IC₅₀ of 22 nM against BRDT. CDD-1349 can be studied in research on nonhormonal contraceptive agent .

HY-N19850

Mammea B/BD	Structural Classification Mammea americana L. Coumarins Phenylpropanoids Plants Calophyllaceae Source Classification	Biochemical Assay Reagents
Mammea B/BD is an anticancer antioxidant that can be isolated from the seeds of Mammea americana. Mammea B/BD exhibits antiproliferative effects on colon cancer cells. Mammea B/BD scavenges DPPH free radicals. Mammea B/BD can be used in colon cancer research .

Cat. No.	Product Name	Chemical Structure

HY-100966S

BD-1008-d5 dihydrobromide

BD-1008-d₅ dihydrobromide is the deuterium labeled BD-1008 dihydrobromide (HY-100966). BD-1008 dihydrobromide is a nonselective σ receptor antagonist with K_is against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 dihydrobromide has an extremely low affinity for the D2 receptor (K_i = 1112 nM) and dopamine transporter (DAT) (K_i > 10,000 nM). BD-1008 dihydrobromide significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 dihydrobromide blocks the self-administration behavior of σ agonists.BD-1008 dihydrobromide can be used for the study of addiction therapy that target the σ receptor .

HY-13204S3

rel-Biperiden EP impurity B-d5
rel-Biperiden EP impurity B-d₅ is deuterium labeled Biperiden (hydrochloride).

HY-143990S

Modafinil EP impurity B-d5
Modafinil EP impurity B-d₅ is the deuterium labeled Modafinil EP impurity B .

HY-145612S

Sudan red 7B-d5
Sudan Red 7B-d5 is a deuterated labeled Sudan red 7B . Sudan red 7B is a red non-fluorescent stain that can be used to stain fat bodies .

HY-W754654

Epothilone B-d3 (synthetic)
Epothilone B-d₃ (synthetic) is the deuterium labeled Epothilone B (HY-17029). Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.

HY-W653975

Bisphenol B-d8
Bisphenol B-d₈ is the deuterium labeled Bisphenol B (HY-W013935). Bisphenol B is a very close structural analog of Bisphenol A (HY-18260), an endocrine disrupting chemical (EDC). Bisphenol B shows endocrine disruptive properties or other adverse effects on animal models .

HY-N7046S

Silybin B-d3

Silybin B-d₃ (Silibinin B-d₃) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-N0479S

Licarin B-d4
Licarin B-d₄ is the deuterium labeled Licarin B (HY-N0479). Licarin B, a nitric oxide production inhibitor extracted from the component of the seeds of Myristica fragrans, improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway .

HY-B1658S

Frovatriptan-d3 hydrochloride
Frovatriptan-d₃ (hydrochloride) is the deuterium labeled Frovatriptan . Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .

HY-18101S

BD-1063-d8 dihydrochloride

BD-1063-d₈ dihydrochloride is the deuterium labeled BD1063 dihydrochloride (HY-18101A) . BD-1063 dihydrochloride is a selective σ-1 receptor antagonist with inhibitory activity against TRPC5 and TRPM3. BD-1063 dihydrochloride exerts anti-hyperalgesic and anti-allodynic effects by inhibiting sustained calcium influx mediated by TRPC5 and TRPM3, and reverses the effects of Carrageenan (HY-125474). BD-1063 dihydrochloride also significantly reduces excessive ethanol self-administration behavior. BD-1063 dihydrochloride is widely used in studies on the mechanisms underlying neuropathic pain, inflammatory hyperalgesia, and alcohol abuse and dependence .

HY-17624S

Framycetin-d2

Framycetin-d₂ (Neomycin B-d₂) is the deuterium labeled Framycetin (HY-17624). Framycetin (Neomycin B), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a K_i of 35 μM. Framycetin competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin inhibits hammerhead ribozyme with a K_i of 13.5 μM. Framycetin, a 5″-azido neomycin B precursor, binds the Drosha site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks